Prognostic Impact of Hypoxia-Inducible miRNA-210 in Patients with Lung Adenocarcinoma

Table 3

Disease-free (a) and overall survival (b) of 62 adenocarcinoma patients according to clinical characteristics and miR-210 expression, analyzed by Cox proportional regression.

(a) Disease-free survival

Variables		Univariate analysis		Multivariate analysis
		HR (95% CI)		HR (95% CI)
Gender	Male/female	2.263 (1.113–4.601)	0.024	3.600 (1.392–9.309)	0.008
Age	≥66/≤65	0.860 (0.427–1.730)	0.672
Tumor size	≥33/<33	2.130 (1.052–4.735)	0.034	2.310 (0.819–6.518)	0.114
T factor	T1/T2–T4	2.232 (1.052–4.735)	0.036	0.469 (0.134–1.645)	0.237
Lymph node	+/−	3.754 (1.857–7.590)	<0.0001	1.038 (0.300–3.589)	0.953
P-stage	I/II-III	4.969 (2.396–10.304)	<0.0001	3.270 (0.894–11.964)	0.073
ly factor	+/−	4.078 (1.822–9.128)	0.001	4.027 (1.229–13.193)	0.021
v factor	+/−	2.768 (1.376–5.566)	0.004	0.994 (0.412–2.398)	0.989
miR-210	High/Low	0.284 (0.134–0.604)	0.001	0.355 (0.148–0.847)	0.02

(b) Overall survival

Variables		Univariate analysis		Multivariate analysis
		HR (95% CI)		HR (95% CI)
Gender	Male/female	3.218 (1.434–7.222)	0.005	2.151 (1.889–14.047)	0.001
Age	≥66/≤65	1.011 (0.473–2.162)	0.977
Tumor size	≥33/<33	2.173 (1.019–4.630)	0.044	1.725 (0.618–4.811)	0.298
T factor	T1/T2–T4	2.988 (1.204–7.415)	0.018	0.801 (0.211–3.039)	0.744
Lymph node	+/−	3.453 (1.614–7.391)	0.001	1.858 (0.499–6.918)	0.356
P-stage	I/II-III	4.533 (2.027–10.138)	<0.0001	1.492 (0.380–5.853)	0.567
ly factor	+/−	3.865 (1.554–9.615)	0.004	3.387 (0.894–12.836)	0.073
v factor	+/−	2.303 (1.075–4.937)	0.032	0.602 (0.226–1.607)	0.311
miR-210	High/low	0.235 (0.099–0.561)	0.001	0.361 (0.127–1.031)	0.057

CI: confidence interval.
< 0.05.